• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cingulate Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/11/25 7:00:34 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CING alert in real time by email
    false 0001862150 0001862150 2025-06-10 2025-06-10 0001862150 CING:CommonStockParValue0.0001PerShareMember 2025-06-10 2025-06-10 0001862150 CING:WarrantsExercisableForOneShareOfCommonStockMember 2025-06-10 2025-06-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 10, 2025

     

    CINGULATE INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-40874   86-3825535
    (State or other jurisdiction   (Commission   (IRS Employer
    of incorporation)   File Number)   Identification No.)

     

    1901 W. 47th Place

    Kansas City, KS 66205

    (Address of principal executive offices) (Zip Code)

     

    (913) 942-2300

    (Registrant’s telephone number, including area code)

     

     

     

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
       

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

      Trading Symbol(s)  

    Name of exchange on which registered

    Common Stock, par value $0.0001 per share   CING  

    The Nasdaq Stock Market LLC

    (Nasdaq Capital Market)

    Warrants, exercisable for one share of common stock   CINGW  

    The Nasdaq Stock Market LLC

    (Nasdaq Capital Market)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    At the Cingulate Inc. (the “Company”) 2025 Annual Meeting of Stockholders held on June 10, 2025 (the “Annual Meeting”), the Company’s stockholders approved Amendment No. 2 to the Cingulate Inc. 2021 Omnibus Equity Incentive Plan (the “Equity Plan”) to increase the number of shares of common stock authorized for issuance thereunder by 800,000 shares (the “Amendment”). The board of directors of the Company had previously approved the Amendment, subject to stockholder approval, and the Amendment became effective upon such stockholder approval.

     

    A copy of the Amendment is included with this Form 8-K as Exhibit 10.1 and is incorporated herein by reference, and the foregoing summary is qualified in its entirety by reference to the terms and provisions of the Amendment.

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    At the Annual Meeting, five proposals were submitted to the Company’s stockholders. The final voting results were as follows:

     

    Proposal 1

     

    The Company’s stockholders elected the following Class I director to serve for a term expiring at the 2028 annual meeting of stockholders and until his successor has been duly elected.

     

    Name  For   Withhold   Broker Non-Votes 
    Peter J. Werth   732,644    42,708    1,663,518 

     

    Proposal 2

     

    The Company’s stockholders approved the ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025.

     

    For   Against   Abstain   Broker Non-Votes 
     2,434,032    1,630    3,208    0 

     

    Proposal 3

     

    The Company’s stockholders approved the Amendment to the Equity Plan to increase the number of shares of common stock authorized for issuance thereunder by 800,000 shares to 1,141,826 shares.

     

    For   Against   Abstain   Broker Non-Votes 
     606,730    165,846    2,776    1,663,518 

     

    Proposal 4

     

    The Company’s stockholders adopted and approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s issued shares of common stock, at a specific ratio, ranging from one-for-two (1:2) to one-for-twenty-five (1:25), at any time prior to the one-year anniversary date of the Annual Meeting, with the exact ratio to be determined by the Board of Directors without further approval or authorization of the Company’s stockholders.

     

    For   Against   Abstain   Broker Non-Votes 
     1,565,119    823,046    50,705    0 

     

     

     

     

    Proposal 5

     

    The Company’s stockholders approved the adjournment of the Annual Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of one or more of foregoing proposals. Adjournment of the Annual Meeting was deemed not necessary, because there were sufficient votes at the time of the Annual Meeting to approve each proposal.

     

    For   Against   Abstain   Broker Non-Votes 
     1,910,553    499,038    29,279    0 

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
         
    10.1   Amendment No. 2 to the Cingulate Inc. 2021 Omnibus Equity Incentive Plan
         
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      CINGULATE INC.
         
    Dated: June 11, 2025 By: /s/ Shane J. Schaffer
      Name: Shane J. Schaffer
      Title:

    Chief Executive Officer

     

     

     

     

    Get the next $CING alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CING

    DatePrice TargetRatingAnalyst
    1/10/2025$12.00Buy
    ROTH MKM
    12/22/2023Buy → Hold
    Laidlaw
    1/20/2022$8.50Buy
    Laidlaw & Co.
    1/11/2022$9.00Buy
    Aegis Capital
    More analyst ratings

    $CING
    SEC Filings

    See more
    • Cingulate Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Cingulate Inc. (0001862150) (Filer)

      6/11/25 7:00:34 AM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cingulate Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement

      8-K - Cingulate Inc. (0001862150) (Filer)

      5/13/25 5:00:21 PM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Cingulate Inc.

      10-Q - Cingulate Inc. (0001862150) (Filer)

      5/8/25 4:40:42 PM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CING
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by EVP and COO Myers Laurie

      4 - Cingulate Inc. (0001862150) (Issuer)

      2/20/25 6:00:04 PM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by SVP and CFO Callahan Jennifer L.

      4 - Cingulate Inc. (0001862150) (Issuer)

      2/20/25 6:00:05 PM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Schaffer Shane J.

      4 - Cingulate Inc. (0001862150) (Issuer)

      2/20/25 6:00:02 PM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CING
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Cingulate with a new price target

      ROTH MKM initiated coverage of Cingulate with a rating of Buy and set a new price target of $12.00

      1/10/25 7:39:52 AM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cingulate downgraded by Laidlaw

      Laidlaw downgraded Cingulate from Buy to Hold

      12/22/23 7:22:08 AM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Laidlaw & Co. initiated coverage on Cingulate with a new price target

      Laidlaw & Co. initiated coverage of Cingulate with a rating of Buy and set a new price target of $8.50

      1/20/22 9:15:46 AM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CING
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer

      Industry Leader with 30+ Years of Experience Will Drive Strategic Growth and Partnerships SCOTTSDALE, Ariz., May 27, 2025 /PRNewswire/ -- Life365, a leading data engagement and virtual care company, today announced the appointment of healthcare executive and investor Jay Roberts as chief development officer. Roberts, who previously served as an executive advisor to Life365, brings more than 30 years of strategic healthcare leadership experience to this pivotal role. Life365's platform enables the next generation of AI-driven healthcare for enterprise healthcare organizations,

      5/27/25 10:05:00 AM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Efficacy Results Announced from Cingulate's Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD

      Subjects Demonstrated Marked Improvement of ADHD Symptoms at Week 5New Drug Application on Schedule for this Summer CING CEO Shares Insights and Strategic Outlook on "Unboxing Biotech" Podcast KANSAS CITY, Kan., May 20, 2025 (GLOBE NEWSWIRE) --  Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced the efficacy results from an FDA required Phase 3, randomized, fixed dose, double blind, placebo controlled clinical study in pediatrics (aged 6-17), for its lead asset CTx-1301 (dexmethylphenidate HCl) for the tre

      5/20/25 8:00:00 AM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301

      Pre-NDA Minutes from April 2, 2025, Meeting Received NDA Submission Planned this Summer KANSAS CITY, Kan., May 14, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced that it has received formal pre-New Drug Application (NDA) meeting minutes from the U.S. Food and Drug Administration (FDA) for it's lead asset CTx-1301 (dexmethylphenidate) for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). "We are pleased that the feedback we received from our pre-NDA meeting wit

      5/14/25 8:00:00 AM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CING
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Callahan Jennifer L. bought $1,490 worth of shares (55 units at $27.10), increasing direct ownership by 2% to 2,333 units (SEC Form 4)

      4 - Cingulate Inc. (0001862150) (Issuer)

      3/22/24 6:00:15 PM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Callahan Jennifer L. bought $3,348 worth of shares (5,000 units at $0.67), increasing direct ownership by 12% to 45,508 units

      4 - Cingulate Inc. (0001862150) (Issuer)

      9/18/23 6:00:26 PM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CING
    Leadership Updates

    Live Leadership Updates

    See more
    • Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer

      Industry Leader with 30+ Years of Experience Will Drive Strategic Growth and Partnerships SCOTTSDALE, Ariz., May 27, 2025 /PRNewswire/ -- Life365, a leading data engagement and virtual care company, today announced the appointment of healthcare executive and investor Jay Roberts as chief development officer. Roberts, who previously served as an executive advisor to Life365, brings more than 30 years of strategic healthcare leadership experience to this pivotal role. Life365's platform enables the next generation of AI-driven healthcare for enterprise healthcare organizations,

      5/27/25 10:05:00 AM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

      KANSAS CITY, Kan., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has appointed three new directors to its board: Jay Roberts, Bryan Lawrence, and Jeff Ervin. The appointment of the new directors follows the completion of the Company's recent follow-on offering of $7.5 million in February 2024, sales under the Company's at-the-market offering (ATM) facility in January 2024 of $3.2 million, as well as the conversion of $3.3 million of outstanding debt i

      2/13/24 6:45:00 AM ET
      $BACK
      $CING
      Medical Specialities
      Health Care
      Biotechnology: Pharmaceutical Preparations